AZothBio

Talentum

Drug development is very lengthy and costly. Saving time and cost,
AZothBio is contributing to the advancement of pharmaceutical industry
by iSTAs’ in-silico analysis and screening technology along with its in-house laboratories’ timely experiment.

Asset Composition

Pipeline Schedule

Pipeline 2021 2022 2023 2024
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
AZBT51105

T Cell Vaccine

In vitro

In vivo

Pre-clinical

License out
AZBR52209

siRNA Delivery

Target analysis

In vitro

In vivo

Pre-clinical

License out
AZBE53206

ER Targeting

Target analysis

In vitro

In vivo

Pre-clinical

License out
AZBF11509

TYK2 Inhibitor

Target analysis

In vitro

In vivo

Pre-clinical

License out
AZBT12128

TRK Inhibitor

Target analysis

In vitro

In vivo

Pre-clinical

License out

Faster discovery & development

Let you make quicker decisions

Customized discovery & optimization

Meet your specific needs and increase efficiency

In-house biochemistry laboratory for in-vitro

Provide you with more consistent and timely results

AZothBio delivers tailored service from A to Z
for making your drug discovery faster and easier.
Conventional Method
5~10 Years

Vs

iSTAs
1.5~2 Years

Our in-house laboratory conducts
timely in vitro & ex vivo verification.
We leverage the efficiency of R&D
through iSTAs.

AZothBio’s in-house laboratories verify
in-silico results biologically and chemically.
Regardless of the success,
all test results go to ArchiSTA for strengthening the database.

Mission Statement

  • We are a team of AI and biochemistry experts dedicated to break down pharmaceutical silos
    by meeting with the unmet needs,‘Lack of Cost-Effective Therapies’.
  • We will continue to put our best efforts to be in line with the global initiatives and UN’s SDG goals

Corporate Identity

위로